Figure 5. Effects of doxorubicin and paclitaxel on the levels of the Raf/MEK/ERK, PI3K/Akt and TP53 pathways in DU145 prostate cancer cells either lacking or containing functional WT-TP53. Western blot analysis was performed to determine the levels of key members of the Raf/MEK/ERK, PI3K/Akt and TP53 pathways in response to treatment with varying concentrations of doxorubicin or paclitaxel for 24 hours. Activation specific antibodies and antibodies measuring total levels of protein were used in these experiments. These experiments were repeated twice, and similar results were observed. The fold values shown in white numbers and letters are presented as averages of 3 densitometric readings. ND = not detected.